Skip to main content


Congratulations to UNC Radiation Oncology physician-scientist Dr. Andrew Wang and collaborator Dr. Seungpyo Hong from the University of Wisconsin-Madison for securing $2.9 million in venture capital to support the commercialization of a laboratory test (Oncosense CTC) they developed to capture cancer cells circulating in the blood.

Using the test, Wang led a pilot study at UNC to gauge patients’ response to radiation treatment or radiation plus chemotherapy. In 35 patients with head and neck cancer, most had fewer circulating tumor cells after treatment than before treatment, a measure of the treatment’s efficacy.

Read more about Oncosense CTC HERE.